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1. Introduction  
Focal segmental glomerulosclerosis (FSGS) is a generic term that can be used to 
describe a morphological/ histological pattern of injury, as well as the name of a 
primary glomerular disease [1]. Histologically, it is characterized by sclerosis, 
hyalinosis, foam cell infiltration, vacuolization of podocytes and podocyte 
infiltration [2]. Primary FSGS represents approximately 40% of idiopathic nephrotic 
syndromes. Although idiopatic nephrotic syndrome is a rare disease with an 
incidence of 7 per 1 million, it often leads to severe renal damage and endstage renal 
disease (ESRD) [3].    
The pathophysiological cause of primary FSGS is still not completely identified [4]. 
Recently, our knowledge of FSGS has changed dramatically with a major focus on the 
podocyte as the starting line of the kidney alteration [5]. In fact, podocyte foot 
process effacement marks the first ultrastructural step related with loss of function 
in glomerular permeability and the typical proteinuria of FSGS. Despite podocyte 
genetic defects are a recognized cause of human FSGS, FSGS also appears in the 
absence of this defects. In some cases, proteinuria may recur after just a few hours 
or days after kidney transplantation. In fact, almost 30% of adult and pediatric FSGS 
patients have post-transplant recurrence [6].   
These findings, allied to the fact that some patients with FSGS respond to treatment 
with plasmapheresis, indicate that there may be a circulating factor that changes the 
glomerular permeability function [7].  
The aim of this review was to study the literature that relates urine and/or serum 
suPAR levels with primary FSGS and post-transplant recurrence in patients with 
FSGS.   
2. Focal segmental glomerulosclerosis:  
2.1. Pathogenesis  
The major feature of FSGS is proteinuria. Indeed, the nephrotic syndrome appears 
at the presentation in about 90% of children and 60% of adults with focal segmental 
glomerulosclerosis. The pathogenesis of focal segmental glomerulosclerosis can be 
divided in two categories: primary and secondary. In both cases, the loss of integrity 
of the glomerular filtration barrier in the glomeruli of the kidney cortex can lead to 
nephrotic proteinuria. This barrier is divided by three layers: the fenestrated 
endothelium, the glomerular basement membrane and the podocytes.  
Podocytes are extremely differentiated and polarized epithelial cells, which integrity 
is given by a central actin cytoskeleton core. In the outer aspect of the glomerular 
wall, they have foot process, linked to each other by a slit diaphragm, composed 
essentially by nephrin. These cells cannot repair by cell division, making podocyte 
depletion a major mediator of glomerulosclerosis [8]. Therefore, changes in 
podocytes morphology and function can lead to FSGS. It starts by retraction of the 
foot processes and extension of the connecting plasma membrane between two feet, 
which leads to podocyte foot process effacement. This can lead to podocytes 
apoptosis and necrosis and develop to loss of glomerulus with scar formation and 
eventual loss of the entire nephron. [5]  
  
2.2. Morphologic variants:  
FSGS has an evident diversity of morphologic lesions, that can differ in their location 
to the vascular and tubular pole, as well as the glomerular hipercellularity and 
capillary collapse [9]. The Columbia Classification is a histologic classification that 
recognizes 5 types: perihilar, cellular, tip, collapsing and not-otherwisespecified, 
which can be applied to primary and secondary forms of FSGS:  
• The cellular variant is featured by a segmental expansible endocapillary 
hypercellularity obliterating capillary lumen, generally with severe 
footprocess effacement. This type is usually associated with primary FSGS 
and is the least common variant.  
• The collapsing variant is defined as a segmental or global implosive collapse 
of glomerular capillaries with hypertrophy and hyperplasia of the overlying 
visceral epithelial cells, sometimes resembling a “pseudo-crescent”. This 
variant has the worst prognostic, with poor rate of response to 
glucocorticoids and a fast course to renal failure.  
• Tip lesions are associated to a single segmental lesion involving the tubular 
pole and are often associated with primary FSGS. It usually presents with 
abrupt onset of the nephrotic syndrome and has the best prognosis, with 
highest responsivity to glucocorticoids and the lowest risk of progression.   
• The perihilar variant is characterized by perihilar hyalinosis and sclerosis at 
the glomerular vascular pole in the majority of glomeruli with segmental 
lesions. It is more common in adaptive FSGS and is related to obesity, reflux 
nephropathy, hypertensive nephrosclerosis, sickle cell anemia and renal 
agenesis.   
• Cases that don’t meet the criteria for the other 4 variants are classified as  
FSGS not otherwise specified (NOS). This is the usual generic form of FSGS.  
The defining lesion of NOS variant is a segmental obliteration of the 
glomerular capillaries by extracellular matrix. Hyalinosis, endocapillary 
foam cells, capsular adhesion and parietal cell coverage of the sclerotic 
lesions can also be present. Several studies suggest this is the most common 
variant. Other variants can evolve into NOS FSGS over time. [10]  
  
  
2.3. Secondary FSGS:  
The secondary causes of FSGS can be divided in four sub-types: Familial or genetic, 
virus-associated, drug-induced and adaptive form.  
Genetic forms of FSGS are due to gene mutations, essentially in nephrin and podocin, 
components of the slit diaphragm [11]. Most mutations have an autosomal recessive 
transmission, which manifests earlier in life. However, autosomal dominant 
transmission (e.g., mutations in genes encoding α-actinin-4 and transient receptor 
potentional cation channel 6) usually presents later. This genetic defects were found 
in approximately 65% of patients with FSGS who presented this histological pattern 
in the first year of life [12].  
Viruses can affect the podocyte by direct infection or by the release of inflammatory 
mediators, like cytokines. Human immunodeficiency virus type 1 (HIV-1) is the most 
studied virus, which directly infects podocytes and tubular epithelial cells [13]. 
Parvovirus B19 is another well-known virus that can infect podocytes and tubular 
cells, leading to a collapsing glomerulopathy [14]. Simian virus 40, cytomegalovirus 
and Epstein-Barr virus are also associated with renal lesion and FSGS.  
Drug-induced FSGS can be associated to heroin abuse [15]. However, FSGS is also 
linked to other drugs, like bisphosphonate pamidronate, an osteoclast inhibitor [16], 
all forms of interferon (alfa, beta and gamma) [17] and mTOR (also known as 
Rapamycin) [18].  
At last, adaptive FSGS is a secondary form that results from structural and functional 
adaptations, mediated by intrarenal vasodilatation, increased glomerular capillary 
pressures and plasma flow rates [19].   
  
2.4. Primary FSGS:  
Primary FSGS has been related to a supposed circulating permeability factor, which 
is suggested by some indirect evidence: the skill to regulate proteinuria by 
immunoadsorption, potential disease recurrence minutes after transplantation,  
therapeutic reduction of proteinuria after plasmapheresis and the induction of 
proteinuria in experimental animals by infusion of patient plasma or its fractions.  
In fact, soluble urokinase-type plasminogen activator factor receptor (suPAR), is 
strongly being suggested as a major candidate. Serum concentrations levels of 
suPAR are higher in patients with FSGS. However, this is not observed in patients 
with minimal change disease (MCD) or membranous nephropathy (MN). Elevated 
serum levels of suPAR (cut-off of 3000 pg/mL) were found in up to 66% of patients 
with FSGS [20].   
  
2.5. Treatment:  
Therapy goal is to induce a complete or partial remission of proteinuria and to 
maintain renal function.   
Pediatric patients with nephrotic syndrome are treated empirically with Prednisone 
(60 mg/m2 per day) for 4-6 weeks.  
Adults usually need a renal biopsy before therapy. Once the diagnosis is made, 
potential secondary causes for nephrotic syndrome must be ruled out. Initial 
therapy of patients with FSGS is RAS blockade and dietary sodium restriction. High 
dose glucocorticoid therapy can be given as 1 mg/ kG of body weight or as 2 mg/kG 
on alternate days. In children, this treatment has the duration of 4-6 weeks and in 
adults of 16 weeks [21]  
In cases of glucocorticoids resistant FSGS and patients with diabetes, psychiatric 
disorder and severe osteoporosis (in which therapy with glucocorticoids has severe 
side effects) the therapy is based in a calcineurin inhibitor, like cyclosporine [22].  
The imunossupressive action of these agents may only have a small role in podocyte 
and glomerular repair. Instead, they have direct effects on podocytes through the 
regulation of survival, maturation and stability pathways. They also are able to 
regulate the expression and distribution of components of the slit diaphragm and 
the cytoskeleton [23]. Additionally, Rituximab has also shown good results in the 
therapy of FSGS. However, this agent may not be effective in steroidresistant FSGS.  
Plasmapheresis and immunoadsorption may be considered in patients who don’t 
respond to severe immunossupressive treatment [24].   
Approximately 40% of patients with primary FSGS and ESRD who undergo a kidney 
transplant, have recurrence of FSGS. There are many risk factors for this event, 
including: younger patients, non-black race, rapid course to ESRD, substantial 
proteinuria in the period before transplant and previous allografts to recurrence.  
In these patients, plasmapheresis can be used at the beginning of recurrence [25].  
3.  The Soluble Urokinase Plasminogen 
Activator Receptor  
  
3.1. Structure and function:  
The urokinase-type plasminogen activator receptor (uPAR) is a 
glycosylphosphatidylinositol (GPI)-linked membrane protein. It contains three 
domains and is present on numerous immunologically active cells like monocytes, 
activated T-lymphocytes and macrophages, but also in endothelial cells, 
keratinocytes, fibroblasts, smooth muscle cells, megakaryocytes and some neoplasic 
cells [26]. uPAR is formed by approximately 90 amino-acids and has three 
homologous domains (DI, DII and DIII) [27]. These domains are encoded by separate 
exon groups of the Plaur gene [28].  
uPAR can bind to many ligands like uPA, Vitronectin, and integrins. By binding to its 
receptor (uPAR), uPA can mediate many cellular functions like adhesion, migration, 
differentiation and proliferation [29].   
Components of full-length uPAR and its ligands interact with integrin co-receptors 
for intracellular signal transduction.  uPA also cleaves uPAR in the linker region 
between D1 and D2, producing a soluble D1 fragment and a membrane-associated 
D2-D3 fragment. uPAR cleavage prevents uPA binding, which can inactivate the 
function of uPAR in proteolysis and also the signaling functions of uPAR [30]. 
Thereby, after the cleavage of the GPI anchor, uPAR is released from the plasma 
membrane as a soluble molecule (suPAR). Its size ranges from 20 to 50 kDa and it is 
found in low concentrations in human fluids under physiologic conditions [5].  Both 
the circulating and membrane-bound forms are directly involved in the regulation 
of cell adhesion and migration through binding of integrins [31]. Indeed, both intact 
and cleaved suPAR variants can have diagnostic and prognostic values in cancer,  
inflammatory and metabolic diseases. [27]   
Podocyte foot process has an actin cytoskeleton, which is connected to the 
glomerular basal membrane by 𝛼3𝛽1, 𝛼v𝛽3 integrin and 𝛼 and 𝛽-dystroglycans. 
Indeed, induction of uPAR intracellular signaling in podocytes can lead to foot 
process effacement and proteinuria by lipid-dependant activation of 𝛼v𝛽3 integrin. 
Therefore, the blockage of 𝛼v𝛽3 integrin can reduce podocyte motility and had 
lowered proteinuria in mice [29].  
Increased activation of the immune system can lead to higher levels of serum suPAR, 
which is also recognized in several conditions like human immunedeficiency virus 
type 1(HIV-1)-infection, malaria,  pneumococcal and streptococcus pneumonia, 
sepsis, bacterial and viral CNS infection, active tuberculosis, and also in various 
forms of solid tumors [30].  
  
3.2. suPAR and a role in FSGS:  
Recent studies describe suPAR as a primary candidate circulating factor in patients 
with primary FSGS. This studies show that total suPAR levels in serum and urine are 
elevated in patients with FSGS, and high serum levels may be associated with 
recurrence in transplanted kidneys [4]. In fact, suPAR can be used to differenciate 
primary FSGS from other causes of kidney disease and serum and urine suPAR can 
have a role in risk stratifying kidney transplant candidates with FSGS or patients 
with native kidney disease undiagnosed [32].  
Wei et al stratified FSGS cases in three sub-populations: primary FSGS, recurrent 
FSGS after transplantation and FSGS without recurrence after transplantation. They 
verified that the highest concentrations of suPAR were found in the 
pretransplantation blood of subjects with FSGS who later developed recurrent FSGS 
after transplantation. It was proposed that pre-transplantation suPAR serum 
concentration may be a predictor of increased risk of recurrence FSGS after 
transplantation. They also concluded that suPAR serum concentrations were 
significantly higher 1 year after transplantation in individuals that developed 
recurrent FSGS than in FSGS patients who received kidney transplants and then had 
normal renal functions. Additionally, although suPAR concentrations correlated 
with the presence of proteinuria, this was not observed with its degree.  
  
3.3. Podocyte foot effacement and uPAR expression:  
Wei et al reported increased Plaur mRNA in glomeruli of patients with FSGS. Indeed, 
mice lacking uPAR (Plaur-/-) were protected from lipopolysaccharide (LPS)- 
mediated induced proteinuria. However, they still developed disease after the 
expression of a constitutively active β3-integrin. This indicates an association 
between the development of podocyte foot effacement and uPAR expression [33].   
  
3.4. A role for β-3 integrin:  
These investigators searched for the presence of active β3-integrin in podocytes, 
using the AP5 antibody, which recognizes an N-terminal epitope of β3-integrin that 
is only available when the integrin is activated. They found that LPS treatment of 
wild-type mice was linked with a strong induction of podocyte AP5 labeling. This 
induction was not observed in LPS-treated Plaur -/- mice [28].   
  
3.5. Circulating and membrane-bound podocyte uPAR in FSGS:  
Other studies addressed if only membrane-bound podocyte uPAR and not 
circulating suPAR could be associated with the pathogenesis of proteinuria and 
FSGS. High-dose recombinant mouse suPARI-III induced proteinuria in Plaur 
knockout mice. In fact, a kidney from these mouse that was transplanted in a 
wildtype mouse developed proteinuria after LPS-induced suPAR production. These 
facts suggests that circulating suPAR is independent of uPAR in the activation of β3-
integrin [6].   
  
3.6. Clinical results supporting a role of suPAR in FSGS:  
Other studies were made to investigate the role of suPAR in human FSGS. It was 
observed an increased activity of β3-integrin when podocytes were exposed to 
serum of patients with recurrent FSGS. Alternatively, when serum from patients 
with complete proteinuria remission after plasmapheresis was used, podocyte 
β3integrin activity was reduced. It was also demonstrated that this activity was 
reduced when it was blocked by antibodies against uPAR and β3-integrin inhibitors 
[34].  
Some other clinical data also support these observations. In fact. Wei et al,  identified 
high serum suPAR levels in patients with primary FSGS, but not in the control group. 
They also described that pre-transplant elevated serum suPAR levels increased risk 
for recurrence FSGS after transplant [6].  
In other study, Wei et al compared serum suPAR concentrations in transplanted 
FSGS patients 1 year after transplant. They found significantly higher suPAR serum 
levels in patients that developed recurrent FSGS , compared to those FSGS patients 
who had normal kidney disease after transplant. They also concluded that serum 
suPAR levels correlated with the presence, but not the degree of proteinuria.  
To analyze if suPAR levels could be decreased by plasmapheresis, Wei et al analysed 
serum from subjects with recurrent FSGS before and after a single treatment of 
plasmapheresis and measured suPAR concentrations. They observed that serum 
suPAR levels were significantly lower. They also tested if plasmapheresis could 
lower podocyte β3 integrin activity by measuring AP5 signal. Indeed, they concluded 
that plasmapheresis could significantly lower podocyte β3 integrin activity caused 
by incubation of podocytes with serum of FSGS patients  
[33].   
Additionally, it was described that urinary suPAR levels of patients with FSGS were 
significantly higher compared to those with other glomerular diseases and normal 
subjects, and positively associated with 24-hour urinary protein excretion in 
primary FSGS [29].   
All these investigations are essential to the supposition that suPAR is the 
fundamental circulating factor involved in FSGS.  
  
3.7. Clinical results not supporting a role of suPAR in FSGS:  
However, some data don’t support this correlation. Indeed, some studies suggests 
that suPAR concentrations are also elevated in minimal change disease (MCD), 
membranous nephrophaty, IgA nephrophaty, lupus nephritis or non-glomerular 
chronic kidney disease (CKD). This suggests that suPAR is also involved in the 
pathogenesis of other glomerular diseases [29]. Other studies found no evidence 
that pre-transplant serum suPAR was different in recurrent FSGS vs non-recurrent 
FSGS, after kidney transplant [32].  Additionally, it was also reported that serum 
suPAR levels were similar before and after the induction of remission [34]. suPAR 
levels are also associated to other illness that are not associated primarily with 
proteinuria, like infections and tumors. Furthermore, ESRD patients may 
accumulate suPAR, which contributes to elevated suPAR levels [5].  
Some FSGS patients without elevated suPAR levels still develop FSGS and recurrent 
FSGS [6].   
  
4.  Conclusion  
Primary FSGS pathogenesis has been associated with a permeability factor for 
several years. suPAR is one of the most probable candidates to corroborate this 
association. Recent studies suggested that serum and urine suPAR levels are 
elevated in patients with primary FSGS and after kidney transplant. Wei et al 
performed a variety of studies that suggests suPAR as a primary mediator of 
podocyte foot effacement. They concluded that both membrane-bound uPAR and 
circulating suPAR can activate β-3 integrin. Other studies suggested that podocyte 
β3-integrin activity and serum suPAR levels were lower after treatments with 
Plasmapheresis.  
More studies are required no confirm if high serum and/or urine suPAR levels are 
specific of FSGS or are shared with other glomerular diseases. Additionally, it should 
be verified if high suPAR levels in FSGS patients with ESRD is due to the 
accumulation of suPAR.   
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